Memorial Sloan-Kettering | GenomeWeb

Memorial Sloan-Kettering

The funding will, in part, support efforts to expand the project's catalog of functional elements and understand their roles in different contexts.

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

This Week in Cell

In Cell this week: double-strand breaks in the mouse genome, metabolomic features of yeast deletion strains, and more.

The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.

The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.

Though the results are preliminary, they suggest that a simpler method that doesn't require isolation of CTCs could potentially be as effective as current CTC-based approaches for AR-V7 testing.

Researchers saw abbreviated overall survival times in estrogen receptor-positive metastatic breast cancer patients with ESR1 mutations in their cell-free DNA.

Immunotherapy Buzz

The New York Times looks at immunotherapy and its use in cancer treatment.

The partners will focus on microbiome drugs for cancer patients undergoing hematopoietic stem cell transplantation or receiving checkpoint inhibitors.

Some 20 percent of 650 clinical germlines analyzed since the project launched last year have had at least one variant associated with increased cancer risk.

Pages

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.